Charles River Laboratories International, Inc. Share Price

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse 21:00:02 24/04/2024 BST 5-day change 1st Jan Change
239.4 USD -0.29% Intraday chart for Charles River Laboratories International, Inc. +3.05% +1.28%
Sales 2024 * 4.22B 340B Sales 2025 * 4.54B 366B Capitalization 12.33B 992B
Net income 2024 * 420M 33.79B Net income 2025 * 525M 42.23B EV / Sales 2024 * 3.39 x
Net Debt 2024 * 1.98B 160B Net Debt 2025 * 1.51B 122B EV / Sales 2025 * 3.05 x
P/E ratio 2024 *
29.6 x
P/E ratio 2025 *
24.1 x
Employees 21,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.19%
More Fundamentals * Assessed data
Dynamic Chart
Charles River Laboratories Files Supplement to Definitive Proxy Statement with the Securities and Exchange Commission CI
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing CI
Zacks Investment Research Adjusts Charles River Laboratories International's Price Target to $259 From $278 MT
Charles River Laboratories International, Inc. and Deciphex Limited Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology CI
Charles River Laboratories, Axovia Therapeutics Collaborate on Developing Rare Disease Gene Therapies MT
Charles River Laboratories International, Inc. Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics CI
Charles River Laboratories Signs Plasmid DNA Manufacturing Deal With Ship of Theseus MT
Charles River Laboratories International, Inc. and Ship of Theseus Announces Good Manufacturing Practice Plasmid DNA Contract Development and Manufacturing Organization Agreement CI
Charles River Laboratories International, Inc Receives a Shareholder Proposal from People for the Ethical Treatment of Animals CI
Deutsche Bank Raises Price Target on Charles River Laboratories to $300 From $275, Keeps Buy Rating MT
Charles River Laboratories International, Inc. Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine CI
Argus Raises Price Target on Charles River Laboratories International to $290 From $200, Maintains Buy Rating MT
Charles River Laboratories International, Navega Therapeutics Partner for Production of AAV-Based Gene Therapy MT
Charles River Laboratories International, Inc. and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration CI
Transcript : Charles River Laboratories International, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:15 AM
More news
1 day-0.93%
1 week+3.48%
Current month-12.12%
1 month-10.36%
3 months+11.73%
6 months+29.65%
Current year+0.72%
More quotes
1 week
223.49
Extreme 223.49
244.56
1 month
223.49
Extreme 223.49
273.57
Current year
201.01
Extreme 201.01
275.00
1 year
161.65
Extreme 161.65
275.00
3 years
161.65
Extreme 161.65
460.21
5 years
95.58
Extreme 95.58
460.21
10 years
49.60
Extreme 49.6
460.21
More quotes
Managers TitleAgeSince
Chief Executive Officer 73 31/12/75
Director of Finance/CFO 51 24/04/22
Chief Operating Officer 54 31/03/89
Members of the board TitleAgeSince
Director/Board Member 78 02/12/07
Director/Board Member 76 31/12/02
Director/Board Member 68 30/09/19
More insiders
Date Price Change Volume
24/04/24 239.4 -0.29% 705 117
23/04/24 240.1 +3.26% 611,881
22/04/24 232.6 +2.55% 544,691
19/04/24 226.8 -0.34% 409,097
18/04/24 227.6 -1.10% 710,218

Delayed Quote Nyse, April 24, 2024 at 04:54 pm

More quotes
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Calendar
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
240.1 USD
Average target price
270.7 USD
Spread / Average Target
+12.72%
Consensus